Logo image of HRMY

HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis

USA - NASDAQ:HRMY - US4131971040 - Common Stock

26.63 USD
-0.21 (-0.78%)
Last: 10/15/2025, 8:00:02 PM
26.41 USD
-0.22 (-0.83%)
After Hours: 10/15/2025, 8:00:02 PM
Fundamental Rating

8

Taking everything into account, HRMY scores 8 out of 10 in our fundamental rating. HRMY was compared to 195 industry peers in the Pharmaceuticals industry. HRMY gets an excellent profitability rating and is at the same time showing great financial health properties. An interesting combination arises when we look at growth and value: HRMY is growing strongly while it also seems undervalued. This makes HRMY very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

HRMY had positive earnings in the past year.
HRMY had a positive operating cash flow in the past year.
Of the past 5 years HRMY 4 years were profitable.
HRMY had a positive operating cash flow in 4 of the past 5 years.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

With an excellent Return On Assets value of 16.33%, HRMY belongs to the best of the industry, outperforming 95.90% of the companies in the same industry.
Looking at the Return On Equity, with a value of 23.40%, HRMY belongs to the top of the industry, outperforming 94.36% of the companies in the same industry.
With an excellent Return On Invested Capital value of 17.95%, HRMY belongs to the best of the industry, outperforming 95.90% of the companies in the same industry.
HRMY had an Average Return On Invested Capital over the past 3 years of 18.27%. This is above the industry average of 15.30%.
Industry RankSector Rank
ROA 16.33%
ROE 23.4%
ROIC 17.95%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

HRMY has a better Profit Margin (23.42%) than 94.36% of its industry peers.
HRMY's Profit Margin has improved in the last couple of years.
HRMY's Operating Margin of 28.72% is amongst the best of the industry. HRMY outperforms 93.85% of its industry peers.
HRMY's Operating Margin has declined in the last couple of years.
HRMY's Gross Margin of 78.34% is amongst the best of the industry. HRMY outperforms 84.62% of its industry peers.
In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
Industry RankSector Rank
OM 28.72%
PM (TTM) 23.42%
GM 78.34%
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HRMY is creating value.
HRMY has more shares outstanding than it did 1 year ago.
HRMY has less shares outstanding than it did 5 years ago.
The debt/assets ratio for HRMY has been reduced compared to a year ago.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

HRMY has an Altman-Z score of 4.77. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.77, HRMY is doing good in the industry, outperforming 78.97% of the companies in the same industry.
The Debt to FCF ratio of HRMY is 0.67, which is an excellent value as it means it would take HRMY, only 0.67 years of fcf income to pay off all of its debts.
HRMY has a Debt to FCF ratio of 0.67. This is amongst the best in the industry. HRMY outperforms 95.90% of its industry peers.
HRMY has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
HRMY has a Debt to Equity ratio (0.20) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 0.67
Altman-Z 4.77
ROIC/WACC2.05
WACC8.77%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

HRMY has a Current Ratio of 3.84. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a Current ratio of 3.84. This is in the better half of the industry: HRMY outperforms 61.54% of its industry peers.
HRMY has a Quick Ratio of 3.80. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a better Quick ratio (3.80) than 63.08% of its industry peers.
Industry RankSector Rank
Current Ratio 3.84
Quick Ratio 3.8
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.76% over the past year.
HRMY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.61% yearly.
Looking at the last year, HRMY shows a quite strong growth in Revenue. The Revenue has grown by 17.74% in the last year.
HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.13% yearly.
EPS 1Y (TTM)49.76%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%240%
Revenue 1Y (TTM)17.74%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%16.01%

3.2 Future

Based on estimates for the next years, HRMY will show a very strong growth in Earnings Per Share. The EPS will grow by 30.22% on average per year.
HRMY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.36% yearly.
EPS Next Y27.25%
EPS Next 2Y27.46%
EPS Next 3Y24.96%
EPS Next 5Y30.22%
Revenue Next Year17.69%
Revenue Next 2Y17.17%
Revenue Next 3Y15.97%
Revenue Next 5Y14.36%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 8.59 indicates a reasonable valuation of HRMY.
Based on the Price/Earnings ratio, HRMY is valued cheaper than 91.79% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.53, HRMY is valued rather cheaply.
A Price/Forward Earnings ratio of 6.53 indicates a rather cheap valuation of HRMY.
Based on the Price/Forward Earnings ratio, HRMY is valued cheaper than 93.33% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HRMY to the average of the S&P500 Index (23.04), we can say HRMY is valued rather cheaply.
Industry RankSector Rank
PE 8.59
Fwd PE 6.53
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

97.95% of the companies in the same industry are more expensive than HRMY, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, HRMY is valued cheaper than 94.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.93
EV/EBITDA 4.56
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HRMY may justify a higher PE ratio.
HRMY's earnings are expected to grow with 24.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y27.46%
EPS Next 3Y24.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HRMY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (10/15/2025, 8:00:02 PM)

After market: 26.41 -0.22 (-0.83%)

26.63

-0.21 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners82.62%
Inst Owner Change0.05%
Ins Owners0.52%
Ins Owner Change-61.56%
Market Cap1.53B
Analysts78.82
Price Target45.44 (70.63%)
Short Float %8.38%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.92%
Min EPS beat(2)-11.17%
Max EPS beat(2)31%
EPS beat(4)3
Avg EPS beat(4)12.28%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)59.09%
EPS beat(12)9
Avg EPS beat(12)123.49%
EPS beat(16)11
Avg EPS beat(16)86.61%
Revenue beat(2)0
Avg Revenue beat(2)-2.22%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)-0.98%
Revenue beat(4)0
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)-0.91%
Revenue beat(8)1
Avg Revenue beat(8)-0.9%
Revenue beat(12)3
Avg Revenue beat(12)-1.17%
Revenue beat(16)4
Avg Revenue beat(16)-1.05%
PT rev (1m)-11.87%
PT rev (3m)-12.66%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)-6.56%
EPS NY rev (1m)-0.38%
EPS NY rev (3m)-5.18%
Revenue NQ rev (1m)-0.46%
Revenue NQ rev (3m)0.56%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-0.32%
Valuation
Industry RankSector Rank
PE 8.59
Fwd PE 6.53
P/S 1.98
P/FCF 5.93
P/OCF 5.91
P/B 1.98
P/tB 2.28
EV/EBITDA 4.56
EPS(TTM)3.1
EY11.64%
EPS(NY)4.08
Fwd EY15.31%
FCF(TTM)4.49
FCFY16.87%
OCF(TTM)4.5
OCFY16.91%
SpS13.43
BVpS13.44
TBVpS11.68
PEG (NY)0.32
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 16.33%
ROE 23.4%
ROCE 23.91%
ROIC 17.95%
ROICexc 45.94%
ROICexgc 63.76%
OM 28.72%
PM (TTM) 23.42%
GM 78.34%
FCFM 33.46%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexcg growth 3Y-76.77%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 0.67
Debt/EBITDA 0.62
Cap/Depr 2.7%
Cap/Sales 0.08%
Interest Coverage 13.83
Cash Conversion 105.45%
Profit Quality 142.89%
Current Ratio 3.84
Quick Ratio 3.8
Altman-Z 4.77
F-Score6
WACC8.77%
ROIC/WACC2.05
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.76%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%240%
EPS Next Y27.25%
EPS Next 2Y27.46%
EPS Next 3Y24.96%
EPS Next 5Y30.22%
Revenue 1Y (TTM)17.74%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%16.01%
Revenue Next Year17.69%
Revenue Next 2Y17.17%
Revenue Next 3Y15.97%
Revenue Next 5Y14.36%
EBIT growth 1Y13.95%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year36.94%
EBIT Next 3Y27.36%
EBIT Next 5Y22.63%
FCF growth 1Y60.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.46%
OCF growth 3Y30.64%
OCF growth 5YN/A